Denali Therapeutics (NASDAQ:DNLI – Free Report) had its price objective cut by HC Wainwright from $90.00 to $87.00 in a ...

Denali Therapeutics Inc. DNLI announced disappointing top-line results from an analysis of Regimen G of the phase II/III ...

Fintel reports that on January 7, 2025, Baird initiated coverage of Denali Therapeutics (NasdaqGS:DNLI) with a Outperform ...

Denali's DNL343 missed efficacy goals in the HEALEY ALS trial but was well-tolerated. Analysts await detailed biomarker data ...

In a report released today, Jessica Fye from J.P. Morgan maintained a Buy rating on Denali Therapeutics (DNLI – Research Report), with a price ...

In a report released today, Thomas Shrader from BTIG maintained a Buy rating on Denali Therapeutics (DNLI – Research Report), with a price ...

Director Vicki L. Sato sold 3,080 shares of the business’s stock in a transaction that occurred on Thursday, January 2nd. The ...

William Blair has initiated coverage on Denali Therapeutics Inc (NASDAQ:DNLI), a company focused on developing drugs for ...

Denali Therapeutics said on Monday its experimental drug failed to meet the main goal of a mid-to-late stage trial involving patients with amyotrophic lateral sclerosis (ALS), a fatal ...

Check the time stamp on this data. Updated AI-Generated Signals for Denali Therapeutics Inc. (DNLI) available here: DNLI.

William Blair starts coverage on Denali Therapeutics with an Outperform rating, citing its transport vehicle platform and promising therapies for neurodegenerative diseases. Denali Therapeutics ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...